PortfoliosLab logoPortfoliosLab logo
HALO vs. SAGE
Performance
Return for Risk
Dividends
Drawdowns
Volatility
Financials

Performance

HALO vs. SAGE - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Halozyme Therapeutics, Inc. (HALO) and Sage Therapeutics, Inc. (SAGE). The values are adjusted to include any dividend payments, if applicable.

Loading graphics...

HALO vs. SAGE - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
HALO
Halozyme Therapeutics, Inc.
-2.82%40.77%29.36%-35.04%41.51%-5.85%140.89%21.19%-27.79%105.06%
SAGE
Sage Therapeutics, Inc.
0.00%59.85%-74.94%-43.18%-10.34%-50.83%19.84%-24.64%-41.84%222.58%

Fundamentals

Market Cap

HALO:

$7.70B

SAGE:

$543.46M

EPS

HALO:

$2.61

SAGE:

-$4.81

PS Ratio

HALO:

5.68

SAGE:

7.72

PB Ratio

HALO:

157.65

SAGE:

1.47

Total Revenue (TTM)

HALO:

$1.40B

SAGE:

$70.41M

Gross Profit (TTM)

HALO:

$1.17B

SAGE:

$63.04M

EBITDA (TTM)

HALO:

$590.37M

SAGE:

-$302.71M

Returns By Period


HALO

1D
1.19%
1M
-6.37%
YTD
-2.82%
6M
-12.73%
1Y
5.71%
3Y*
19.64%
5Y*
9.04%
10Y*
20.96%

SAGE

1D
1M
YTD
6M
1Y
3Y*
5Y*
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Halozyme Therapeutics, Inc.

Sage Therapeutics, Inc.

Return for Risk

HALO vs. SAGE — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

HALO
HALO Risk / Return Rank: 4343
Overall Rank
HALO Sharpe Ratio Rank: 4545
Sharpe Ratio Rank
HALO Sortino Ratio Rank: 4040
Sortino Ratio Rank
HALO Omega Ratio Rank: 4343
Omega Ratio Rank
HALO Calmar Ratio Rank: 4242
Calmar Ratio Rank
HALO Martin Ratio Rank: 4343
Martin Ratio Rank

SAGE
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

HALO vs. SAGE - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Halozyme Therapeutics, Inc. (HALO) and Sage Therapeutics, Inc. (SAGE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


HALOSAGEDifference

Sharpe ratio

Return per unit of total volatility

0.13

Sortino ratio

Return per unit of downside risk

0.47

Omega ratio

Gain probability vs. loss probability

1.08

Calmar ratio

Return relative to maximum drawdown

0.08

Martin ratio

Return relative to average drawdown

0.17

HALO vs. SAGE - Sharpe Ratio Comparison


Loading graphics...

Sharpe Ratios by Period


HALOSAGEDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

0.13

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

0.23

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.48

Sharpe Ratio (All Time)

Calculated using the full available price history

0.23

Correlation

The correlation between HALO and SAGE is 0.39, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


Dividends

HALO vs. SAGE - Dividend Comparison

Neither HALO nor SAGE has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

HALO vs. SAGE - Drawdown Comparison


Loading graphics...

Drawdown Indicators


HALOSAGEDifference

Max Drawdown

Largest peak-to-trough decline

-74.26%

Max Drawdown (1Y)

Largest decline over 1 year

-31.69%

Max Drawdown (5Y)

Largest decline over 5 years

-49.06%

Max Drawdown (10Y)

Largest decline over 10 years

-49.06%

Current Drawdown

Current decline from peak

-19.49%

Average Drawdown

Average peak-to-trough decline

-32.02%

Ulcer Index

Depth and duration of drawdowns from previous peaks

14.78%

Volatility

HALO vs. SAGE - Volatility Comparison


Loading graphics...

Volatility by Period


HALOSAGEDifference

Volatility (1M)

Calculated over the trailing 1-month period

9.11%

Volatility (6M)

Calculated over the trailing 6-month period

23.48%

Volatility (1Y)

Calculated over the trailing 1-year period

43.82%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

39.51%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

43.38%

Financials

HALO vs. SAGE - Financials Comparison

This section allows you to compare key financial metrics between Halozyme Therapeutics, Inc. and Sage Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.00100.00M200.00M300.00M400.00M500.00MAprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober
451.77M
31.66M
(HALO) Total Revenue
(SAGE) Total Revenue
Values in USD except per share items